Literature DB >> 22250925

Cognitive factors and willingness to participate in an HIV vaccine trial among HIV-positive injection drug users.

Shayesta Dhalla1, Gary Poole, Joel Singer, David M Patrick, Thomas Kerr.   

Abstract

There are gaps in our knowledge of the role cognitive factors play in determining people's willingness to participate (WTP) in therapeutic HIV vaccine trials. Using a cross-sectional study of HIV-positive injection drug users (IDU), we determined the role of three cognitive factors: HIV treatment optimism, self-efficacy beliefs, and knowledge of vaccine trial concepts in relation to WTP in a hypothetical phase 3 therapeutic HIV vaccine trial. WTP was 54%. Participants tended to be low in HIV treatment optimism (mean = 3.9/10), high in self-efficacy (mean = 79.8/100), and low in knowledge (mean = 4.1/10). Items pertaining to HIV treatment optimism and knowledge of HIV vaccine trial concepts were generally unrelated to WTP. An increase in self-efficacy had a statistically significant positive association with WTP (OR = 1.61, 95% CI = 1.04-2.46, p < 0.05). Furthermore, most of these HIV-positive participants had high levels of self-efficacy, so we are most confident about this relationship at such levels. These findings indicate that interventions focused on increasing self-efficacy could enhance WTP among HIV-positive IDU.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22250925      PMCID: PMC3290734          DOI: 10.1080/13548506.2011.608803

Source DB:  PubMed          Journal:  Psychol Health Med        ISSN: 1354-8506            Impact factor:   2.423


  22 in total

1.  A scale of optimism-scepticism in the context of HIV treatments.

Authors:  P Van de Ven; J Crawford; S Kippax; S Knox; G Prestage
Journal:  AIDS Care       Date:  2000-04

2.  Who will enroll? Predicting participation in a phase II AIDS vaccine trial.

Authors:  S D Halpern; D S Metzger; J A Berlin; P A Ubel
Journal:  J Acquir Immune Defic Syndr       Date:  2001-07-01       Impact factor: 3.731

3.  Therapeutic vaccination in primary HIV infection, the Quest trial.

Authors:  Luc Perrin
Journal:  Vaccine       Date:  2002-05-06       Impact factor: 3.641

4.  Determinants of HAART discontinuation among injection drug users.

Authors:  T Kerr; A Marshall; J Walsh; A Palepu; M Tyndall; J Montaner; R Hogg; E Wood
Journal:  AIDS Care       Date:  2005-07

Review 5.  Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine.

Authors:  Glenda Gray; Susan Buchbinder; Ann Duerr
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

6.  Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial.

Authors:  K Harrison; D Vlahov; K Jones; K Charron; M L Clements
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-11-01

7.  Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial.

Authors:  J O Kahn; D W Cherng; K Mayer; H Murray; S Lagakos
Journal:  JAMA       Date:  2000-11-01       Impact factor: 56.272

8.  Highly active antiretroviral therapy (HAART). Awareness and beliefs about infectivity and the influence on sexual behaviour in the general population of Sweden.

Authors:  C A Herlitz; J L Steel
Journal:  Eur J Public Health       Date:  2001-09       Impact factor: 3.367

9.  Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART.

Authors:  Robert Horne; Deanna Buick; Martin Fisher; Heather Leake; Vanessa Cooper; John Weinman
Journal:  Int J STD AIDS       Date:  2004-01       Impact factor: 1.359

10.  Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States.

Authors:  B A Koblin; P Heagerty; A Sheon; S Buchbinder; C Celum; J M Douglas; M Gross; M Marmor; K Mayer; D Metzger; G Seage
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

View more
  5 in total

1.  Enhanced retention strategies and willingness to participate among hard-to-reach female sex workers in Barcelona for HIV prevention and vaccine trials.

Authors:  M Florencia Etcheverry; Jennifer L Evans; Emilia Sanchez; Eva Mendez-Arancibia; Mercé Meroño; José M Gatell; Kimberly Page; Joan Joseph
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

2.  Willingness to participate in HIV therapeutic vaccine trials among HIV-infected patients on ART in China.

Authors:  Yuan Dong; Xiaoxing Shen; Ruizhang Guo; Baochi Liu; Lingyan Zhu; Jing Wang; Linxia Zhang; Jun Sun; Xiaoyan Zhang; Jianqing Xu
Journal:  PLoS One       Date:  2014-11-05       Impact factor: 3.240

3.  Willingness to Participate in Hypothetical HIV Vaccine Trial and Associated Factors among People Who Inject Drugs in Dar es Salaam, Tanzania.

Authors:  Masunga K Iseselo; Edith A M Tarimo; Eric Sandstrom; Asli Kulane
Journal:  Biomed Res Int       Date:  2020-07-02       Impact factor: 3.411

4.  A little shot of humility: Intellectual humility predicts vaccination attitudes and intention to vaccinate against COVID-19.

Authors:  Ho P Huynh; Amy R Senger
Journal:  J Appl Soc Psychol       Date:  2021-02-12

5.  What motivates or demotivates injecting drug users to participate in hypothetical HIV vaccine efficacy trials? A qualitative study from urban Tanzania.

Authors:  Masunga K Iseselo; Edith Am Tarimo; Eric Sandstrom; Asli Kulane
Journal:  East Afr Health Res J       Date:  2020-11-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.